$A phase 1b study of intraperitoneal oncolytic viral immunotherapy in platinum-resistant or refractory ovarian cancer$

A phase 1b study of intraperitoneal oncolytic viral immunotherapy in platinum-resistant or refractory ovarian cancer

Our objective was to assess safety and adverse events associated with intraperitoneal Olvi-Vec virotherapy in patients with platinum-resistant or refractory ovarian cancer (PRROC). Secondary objectives included objective response rate (ORR) per RECIST 1.1 and progression-free survival (PFS). Olvi-Ve...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Gynecologic oncology 2021-12, Vol.163 (3), p.481-489
Hauptverfasser:	Manyam, Madhavi, Stephens, Amanda J, Kennard, Jessica A, LeBlanc, Jane, Ahmad, Sarfraz, Kendrick, James E, Holloway, Robert W
Format:	Artikel
Sprache:	eng
Schlagworte:	Aged Carcinoma, Ovarian Epithelial - immunology Carcinoma, Ovarian Epithelial - therapy Carcinoma, Ovarian Epithelial - virology Dose-Response Relationship, Drug Drug Resistance, Neoplasm Female Humans Immunotherapy - methods Infusions, Parenteral Middle Aged Neoplastic Cells, Circulating - pathology Oncolytic Virotherapy - methods Oncolytic Viruses - immunology Oncolytic Viruses - physiology Organoplatinum Compounds - pharmacology Ovarian Neoplasms - immunology Ovarian Neoplasms - pathology Ovarian Neoplasms - therapy Ovarian Neoplasms - virology Progression-Free Survival Vaccinia virus - immunology Vaccinia virus - physiology
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!